Scottish Medicines Consortium accepts six new medicines for routine use in NHS Scotland

The Scottish Medicines Consortium (SMC) has published advice accepting six new medicines for routine use by NHS Scotland, including treatments for mantle cell lymphoma, chronic lymphocytic leukaemia and high cholesterol.  These medicines include: Ibrutinib (Imbruvica) for the treatment of mantle cell lymphoma (MCL). Ibrutinib was accepted after consideration under SMC’s Patient and Clinician Engagement process (PACE) for medicines that treat end of life and very rare conditions. MCL is an extremely rare, incurable, aggressive form of non-Hodgkin’s lymphoma (NHL). In the PACE meeting, patient groups and clinicians spoke of how there are limited effective treatment options for this condition, which